FDA Approves ANDA for Verapamil Hydrochloride by Knack
The FDA has approved the ANDA220076 for Verapamil Hydrochloride submitted by Knack.
Published: July 29, 2026
Updated: July 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Calcium Channel Blocker
Asset: Knack
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Knack
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Knack's ANDA for Verapamil Hydrochloride introduces a new competitor in the cardiovascular market. This could impact existing players' market share and pricing strategies, necessitating a proactive response from portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and initial sales performance of Knack's Verapamil Hydrochloride.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.